Citius Oncology, Inc.
CTORNASDAQHealthcare● Active
$0.80
+$0.02(+2.55%)
Market Cap$74375662
P/E Ratio—
52W High$6.19
52W Low$0.491
Citius Oncology, Inc.（CTOR）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · CTOR · 截至 2026-06-09
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-09 | 2024-09 | 2023-09 | 2022-09 |
|---|---|---|---|---|
| Revenue | ||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | — |
| Operating Expenses | ||||
| R&D Expenses | $0.01B | $0.00B | $0.00B | $0.01B |
| G&A Expenses | $0.02B | $0.02B | $0.01B | $0.00B |
| Total Operating Expenses | $0.02B | $0.02B | $0.01B | $0.01B |
| Operating Income | ($0.02B) | ($0.02B) | ($0.01B) | ($0.01B) |
| Operating Margin %(computed) | — | — | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.02B) | ($0.02B) | ($0.01B) | ($0.01B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.02B) | ($0.02B) | ($0.01B) | ($0.01B) |
| Net Margin %(computed) | — | — | — | — |
| Per Share & EBITDA | ||||
| EPS (Basic) | $-0.34 | $-0.30 | $-0.19 | $-0.08 |
| Wtd Avg Shares | 0.07B | 0.07B | 0.09B | 0.09B |
| EBITDA | ($0.02B) | ($0.02B) | ($0.01B) | $0.00B |
| EBITDA Margin %(computed) | — | — | — | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-09 · USD · B
深入了解Citius Oncology, Inc.
关于Citius Oncology, Inc.（CTOR）损益表
Citius Oncology, Inc.（CTOR）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，CTOR实现营收$0.00B，毛利润$0.00B（毛利率—），净利润($0.02B)（净利率—）。
常见问题
CTOR · 4 问Citius Oncology, Inc.（CTOR）2025财年营收为$0.00B，同比down—%。
CTOR revenueCTOR salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09